glp-1 manufacturers in india emerging as a key backend and manufacturing hub for obesity drugs. Pharma players positioned across brands, APIs, peptides & CDMO value chain. Long-term opportunity driven by global obesity and diabetes Government Steps Up Oversight as

Ozempic lawsuit updates timeline 7.01.26 MDL numbers grew leading into July The GLP-1 RA MDL has 3,848 pending actions

Care 11, 491499

With liraglutide established as an effective treatment that also addresses the dysmetabolic prediabetic-like state that characterizes these patients, it is my hope that physicians will have the condition on their radar and discuss this new treatment option with relevant patients

BMI 30.0 to 34.9 (class I obesity)

The FDA approved liraglutide (Victoza) at doses of 0.6 mg, 1.2 mg, and 1.8 mg daily for T2DM patients with unsatisfactory diet or exercise control, and 2.4 mg and 3 mg as a chronic weight management drug

Propensity score matching (PSM) was used to create matched cohorts for age, hepatic encephalopathy (HE), esophageal variceal (EV) bleeding, hepatorenal syndrome (HRS), and MELD-Na parameters, including sodium, bilirubin, INR, and need for dialysis